MAP2K7 and non-small cell lung carcinoma: Metapristone suppressed non-small cell lung cancer (NSCLC) cell growth and metastasis by targeting epidermal growth factor receptor (EGFR)-mediated PI3K/AKT pathway [38] and modulating RAS/RAF/MEK/MAPK pathway [39].